Search filters

List of works by Peter Hillmen

A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia

scientific journal article

A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relap

scientific article

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

scientific article published on 7 December 2015

Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib

scientific article published on 01 May 2019

Advancing therapy for chronic lymphocytic leukemia--the role of rituximab

scientific article published on February 2004

Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia

scientific article published on 5 November 2007

Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial

scientific article published on 09 April 2012

Alemtuzumab therapy in B-cell lymphoproliferative disorders

scientific article

Altered natural killer cell subset homeostasis and defective chemotactic responses in paroxysmal nocturnal hemoglobinuria

scientific article published on 23 July 2013

Assessing minimal residual disease in chronic lymphocytic leukemia

scientific article published on January 2008

Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial ⬇️

scientific article published on 22 August 2017

Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry

scientific article

Beyond detectable minimal residual disease in chronic lymphocytic leukemia

scientific article

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration

scientific article

CD52 expression patterns in myeloma and the applicability of alemtuzumab therapy

scientific article published on 17 October 2006

Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia

scientific article published in March 2002

Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials ⬇️

scientific article

Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial ⬇️

scientific article published on 20 September 2016

Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial

scientific article published on 14 April 2015

Chronic lymphocytic leukaemia—moving towards cure? ⬇️

scientific article published on October 2, 2010

Clinical and diagnostic implications of monoclonal B-cell lymphocytosis

scientific article published on March 2010

Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, ⬇️

scientific article

Clonal lymphocytes in persons without known chronic lymphocytic leukemia (CLL): implications of recent findings in family members of CLL patients

scientific article published in July 2004

Diagnosis and management of paroxysmal nocturnal hemoglobinuria

scientific article

Diagnostic criteria for monoclonal B-cell lymphocytosis

scientific article

Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia

scientific article published on 20 November 2003

Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization

scientific article

Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria

scientific article published on 8 March 2010

Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria

scientific article published in February 2004

Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study

scientific article published on 21 January 2020

Eradicating minimal residual disease in chronic lymphocytic leukemia: should this be the goal of treatment?

scientific article published on January 2010

Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation ⬇️

scientific article published on 29 December 2016

Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival

scientific article published on 28 February 2005

Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials

scientific article published on 05 June 2018

Experiences in the design and implementation of phase II trials in CLL.

scientific article

Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia

scientific article

Future prospects for fludarabine-containing regimens in the treatment of hematological cancers

scientific article published on January 2004

GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial ⬇️

scientific article published on 26 July 2017

Guidelines for diagnosis, indications for treatment, response assessment and supportive management of chronic lymphocytic leukemia

scientific article published on 14 March 2018

Guidelines for the diagnosis and management of adult aplastic anaemia

scientific article

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

scientific article

Health-related quality of life and patient-reported outcomes of ofatumumab plus chlorambucil versus chlorambucil monotherapy in the COMPLEMENT 1 trial of patients with previously untreated CLL.

scientific article published on 5 August 2016

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia ⬇️

scientific article

Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.

scientific article

Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study

scientific article published on 13 September 2016

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia

scientific article

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

scientific article

Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial

scientific article

Immune-mediated hemolytic anemia

scientific article

Immunological effects and safe administration of alemtuzumab (MabCampath) in advanced B-cLL.

scientific article

Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.

scientific article

Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion

scientific article published in October 2002

Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab

scientific article published on 06 March 2019

Long‐term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria ⬇️

scientific article published on April 25, 2013

Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia

scientific article published on March 2004

Minimal residual disease and survival in chronic lymphocytic leukemia.

scientific article

Minimal residual disease assessment in chronic lymphocytic leukaemia

scientific article published on September 2007

Minimal residual disease in chronic lymphocytic leukaemia: is it ready for primetime?

scientific article published on 27 November 2006

Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts

scientific article

Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia

scientific article

Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria

scientific article

Natural killer (NK) cell function in paroxysmal nocturnal hemoglobinuria: a deficiency of NK cells, but not an NK cell deficiency ⬇️

scientific article

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia

scientific article

Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia

scientific article

Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study

scientific article published on 13 March 2015

Outreach monitoring service for patients with indolent B-cell and plasma cell disorders: a UK experience

scientific article published on 25 October 2007

Paroxysmal nocturnal hemoglobinuria--hemolysis before and after eculizumab

scientific article published on December 2010

Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia

scientific article

Phase 1b Study of Tirabrutinib in Combination With Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia

scientific article published on 10 March 2020

Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia

scientific article published on 12 March 2019

Polymyalgia rheumatica development in a patient under PI3K inhibitor therapy for chronic lymphocytic leukaemia

scientific article published on 8 November 2017

Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH).

scientific article published on 31 July 2003

Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials

scientific article published on 22 February 2018

Protection of erythrocytes from human complement-mediated lysis by membrane-targeted recombinant soluble CD59: a new approach to PNH therapy

scientific article

Recent advances in the diagnosis, monitoring, and management of patients with paroxysmal nocturnal hemoglobinuria

scientific article published on September 2007

Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria

scientific article published on May 2007

Response: Additional data needed for a better understanding of the potential relationship between atrial fibrillation and ibrutinib

scientific article published in March 2015

Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study

scientific article

Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma

Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial

scientific article

Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP.

scientific article published in April 2005

Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria

scientific article

Targeted Therapy for Chronic Lymphocytic Leukemia: A Glimpse Into the Future ⬇️

scientific article published on December 19, 2011

The biological and clinical relationship between CD5+23+ monoclonal B-cell lymphocytosis and chronic lymphocytic leukaemia

scientific article published on December 2007

The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease

scientific article

The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria

scientific article

The glycosylphosphatidylinositol anchor and paroxysmal nocturnal haemoglobinuria/aplasia model

scientific article

The management of paroxysmal nocturnal hemoglobinuria: recent advances in diagnosis and treatment and new hope for patients

scientific article

The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab

scientific article published on January 2009

The role of complement inhibition in PNH.

scientific article published on January 2008

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

scientific article

Under-recognized complications in patients with paroxysmal nocturnal haemoglobinuria: raised pulmonary pressure and reduced right ventricular function

scientific article published on 29 May 2012

Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia

Scientific article published on 2 Dec 2016

Using the biology of chronic lymphocytic leukemia to choose treatment

scientific article published on January 2011

Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study

scientific article published on 28 September 2020

Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial

scientific article published in May 2018

Which patients with paroxysmal nocturnal hemoglobinuria (PNH) should be treated with eculizumab? ASH evidence-based review 2008.

scientific article published on January 2008

Paulina is supported by:

About Paulina

Help